23andMe Holding Co.
(NASDAQ : ME)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 2.30%353.600.0%$6728.26m
BNTXBioNTech SE 5.04%328.350.0%$1093.01m
SNSSSunesis Pharmaceuticals, Inc. -2.32%10.520.7%$735.39m
NVAXNovavax, Inc. -2.54%179.3379.8%$649.04m
AMGNAmgen, Inc. -0.38%241.541.3%$499.24m
BIIBBiogen, Inc. -0.74%326.731.7%$431.26m
VRTXVertex Pharmaceuticals, Inc. 0.60%201.581.9%$414.73m
GILDGilead Sciences, Inc. -2.21%68.291.0%$401.30m
REGNRegeneron Pharmaceuticals, Inc. -1.46%574.612.7%$353.89m
ILMNIllumina, Inc. 0.84%495.753.5%$264.01m
NTLAIntellia Therapeutics, Inc. 3.53%141.852.3%$263.90m
CRSPCRISPR Therapeutics AG 1.70%121.020.6%$144.72m
EXASEXACT Sciences Corp. -3.64%107.8418.1%$123.59m
SGENSeagen Inc. 4.38%153.395.8%$120.23m
CYTKCytokinetics, Inc. 1.09%29.683.2%$115.29m

Company Profile

23andMe Holding Co. is consumer genetics and research company, which engages to help people access, understand, and benefit from the human genome. It provides direct access to consumer genetic testing through its Personal Genome Service, and also food and drug administration authorizations for genetic health risk reports. The firm’s research platform has generated publications on the genetic underpinnings of a range of diseases, conditions, and traits. The platform also powers the 23andMe therapeutics group, pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. The company was founded by Anne E. Wojcickiin 2006 and is headquartered in Sunnyvale, CA.